Demographic characteristics of progressors to ESLD (cases) and nonprogressors (controls)
. | Progressors (n = 10) . | Nonprogressors (n = 10) . | P . |
|---|---|---|---|
| Race, no. (%) | |||
| Caucasian | 10 (100) | 6 (60) | NS |
| Other | — | 4 (40) | |
| HIV+, no. (%) | 8 (80) | 8 (80) | NS |
| HCV viral load, bDNA, mean copies/mL (range) | 2.27e + 07 (5.19e + 05 to 6.88e + 07) | 2.38e + 07 (5.55e + 05 to 8.96e + 07) | NS |
| HCV subtypes* | |||
| 1 | 1 | 1 | NS |
| 1a | 4 | 7 | |
| 1b | 5 | 2 | |
| Baseline CD4+, mean cells/mL (range) | 525 (249-1388) | 417 (212-680) | NS |
| Baseline CD8+, mean cells/mL (range) | 698 (277-1379) | 922 (133-2592) | NS |
| Time from baseline to follow-up, mean y, (range) | 7.82 (4.7-13.9) | 10.71 (6.1-14.3) | .01 |
| Baseline AST, mean U/L (range) | 70 (38-128) | 47.6 (29-64) | NS |
| Baseline ALT, mean U/L (range) | 90 (48-130) | 87 (34-197) | NS |
. | Progressors (n = 10) . | Nonprogressors (n = 10) . | P . |
|---|---|---|---|
| Race, no. (%) | |||
| Caucasian | 10 (100) | 6 (60) | NS |
| Other | — | 4 (40) | |
| HIV+, no. (%) | 8 (80) | 8 (80) | NS |
| HCV viral load, bDNA, mean copies/mL (range) | 2.27e + 07 (5.19e + 05 to 6.88e + 07) | 2.38e + 07 (5.55e + 05 to 8.96e + 07) | NS |
| HCV subtypes* | |||
| 1 | 1 | 1 | NS |
| 1a | 4 | 7 | |
| 1b | 5 | 2 | |
| Baseline CD4+, mean cells/mL (range) | 525 (249-1388) | 417 (212-680) | NS |
| Baseline CD8+, mean cells/mL (range) | 698 (277-1379) | 922 (133-2592) | NS |
| Time from baseline to follow-up, mean y, (range) | 7.82 (4.7-13.9) | 10.71 (6.1-14.3) | .01 |
| Baseline AST, mean U/L (range) | 70 (38-128) | 47.6 (29-64) | NS |
| Baseline ALT, mean U/L (range) | 90 (48-130) | 87 (34-197) | NS |
NS indicates not significant.
Three patients exhibited genotype shifts during the study period: one from 1a to 1b, one from 1b to 1a, and one from 1b to 1.24